



Strengthening STD Prevention and Control for Health Departments

Form Approved
OMB No. 0920-1282

Expiration Date: TBD

STD PCHD Performance Measurement Year 5

Project Area (Select from dropdown):


Period of Performance: January 1, 2024 to December 31, 2024

Submission Date (mm/dd/yyyy):

If other reporting period, or if varies by
performance measure, describe:

Other comments related to this submission
(optional):

Click a tab at the bottom of the workbook to jump to the corresponding worksheet.



Instructions:

Please use this template to prepare a **STD PCHD Performance Measures submission for DSTDP**. There is an optional "Feedback" tab we have provided for you to comment on the updates the STD PCHD Team has made to this template. Please refer to the supplemental guidance document for information on the rationale for requesting these data, how the data will be used, and how to complete each worksheet. Furthermore, the supplemental guidance document indicates where there are changes to either the variable requested or clarifications made on how to report on a specific variable.

Applicants will complete and submit performance measures each year.

If you need technical support at any time, please send an email with a detailed description of your need to the following address:

STD_PCHD@cdc.gov

Notes on Data Entry:

All light pink cells are available for user input. Please complete them to the best of your ability.

Gray cells are auto-calculated or pre-populated based on information provided.

Drop-down menus are included in all worksheets, and they should be identifiable through a downward arrow that appears when you select it.

The core performance measures in each worksheet are bolded. Measures that are auto-calculated but not considered core performance measures are italicized (not bolded).

kkk

Saving and Submitting Your Work:

Please save this file as "[ProjectAreaName]_Performance.Measures.2023_yy-mm-dd" and as an .xlsm version. (Note: if you save this file as an .xls or .xlsx document type, the template may no longer automatically expand and collapse the height of rows to fit text.)

To submit this document, save a copy of the file ending in .xls or .xlsx as a Grant Note in GrantSolutions by the deadline provided by DSTDP. Please submit a courtesy copy to your DSTDP project officer as well by **October 7, 2024**.

Relevant Links:

To access the series of Technical Assistance Notes for the PS19-1901 STD PCHD strategies, click here:

[PS19-1901 STD PCHD Technical Assistance Notes](#)

To find general information on using Microsoft Excel:

[Microsoft Excel Basics](#)

Privacy Act Statement and Reporting Burden

This information is collected under the authority of the Public Health Service Act, Section 301, "Research and Investigation," (42 U.S.C. 241); and Sections 304, 306 and 308(d) which discuss authority to maintain data and provide assurances of confidentiality for health research and related activities (42 U.S.C. 242 b, k, and m(d)). This information is also being collected in conjunction with the provisions of the Government Paperwork Elimination Act and the Paperwork Reduction Act (PRA). This information will only be used by the Centers for Disease Control and Prevention (CDC) staff to monitor recipient's progress under cooperative agreement PS19-1901 STD PCHD.

Public reporting burden of this collection of information is estimated to average 30 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; Attn: OMB-PRA (0920-1282).

Surveillance		
Line No.	Pregnancy Ascertainment	Data Fields
a_10	Total number of female syphilis cases (all stages) reported in the project area in the reporting period	0
a_11	Total number of female syphilis cases (all stages) with pregnancy status documented as "Yes, pregnant"	
a_12	Total number of female syphilis cases (all stages) with pregnancy status documented as "No, not pregnant"	
a_13	Total number of female syphilis cases (all stages) with pregnancy status documented as "Unknown" or "Missing"	
a_14	<i>Percent of female syphilis cases (all stages) that had pregnancy status documented as "Yes, pregnant" or "No, not pregnant"</i>	Enter Denominator
a_15	Is your surveillance and/or case management system able to document when pregnancy status was obtained?	
a_16	If yes (a_15): Total number of female syphilis cases (all stages) with pregnancy status documented as "Yes, pregnant" or "No, not pregnant" within 14 days of specimen collection	
a_17	Among all female syphilis cases (all stages), % with pregnancy status documented as "Yes, pregnant" or "No, not pregnant" within 14 days of specimen collection	Enter Denominator
a_18	Indicate the quality of the data above by selecting an answer from the dropdown menu.	
a_19	Any data limitations, including reasons unable to report (text response)	

Congenital Syphilis		
Line No.	Potential Cases Averted	Data Fields
b_1	<u>Total number of females with syphilis (all stages) in the project.</u>	0
b_2	<u>Total number of pregnant females with syphilis (all stages). (To</u>	0
b_3	% of total female syphilis cases that were pregnant	Enter Denominator
b_4	Total number of reported congenital syphilis cases and stillbirths	
b_5	Total number of potential congenital syphilis cases averted	0

b_6	Among all potential congenital syphilis cases, % averted	Enter Denominator
b_7	Indicate the quality of the data above by selecting an answer from the dropdown menu.	
b_8	Any data limitations, including reasons unable to report (text response)	

Outbreak Response		
Line No.	Disease Investigation and Intervention	Data Fields
	Active or Initiated STD Outbreak Response Plan(s)	
c_1	Does the project area have an STD outbreak plan in place? [Select from dropdown. If no , please skip to the section "Staff assignments to assist other outbreaks" (c_6)]	
c_2	Total number of times that the outbreak plan was active or initiated for syphilis by the project area in the reporting period	
c_3	Total number of times that the outbreak plan was active or initiated for GC in the reporting period	
c_4	Total number of times that the outbreak plan was active or initiated for <u>another STD</u> in the reporting period	

c_5	Total number of times that the outbreak plan was active or initiated for an STD	0
Line No.	Staff Deployments to Assist Other Outbreaks	Data Fields
c_6	Total number of STD program staff deployed on temporary, formal assignments to assist with HIV, Hepatitis, or TB outbreaks during the reporting period	
c_7	Total number of STD program staff deployed on temporary, formal assignments to assist with non-STD (e.g. foodborne, etc.) outbreaks during the reporting period	
c_8	Total number of STD staff deployed for all outbreaks of all types (STD and non-STD)	0
c_8a	Among all STD program staff deployed, % STD staff deployed for a non-STD outbreak	Enter Denominator
c_9	Total number of outbreak responses (HIV, Hepatitis, TB, or other conditions) for which those staff were formally assigned to assist during the period.	

Line No.	Data Quality	Data Fields
c_10	Indicate the quality of the data above by selecting an answer from the dropdown menu.	
c_11	Any data limitations, including reasons unable to report (text response)	

Early Syphilis Cases: Disease Investigation and Intervention

Line No.	Key Populations	Pregnant Females under Age 45	Other Females under Age 45	Men with only Female Partners (MSW)	Men with Male Partners (MSM and MSMW)	Sum Totals (auto-calculated)
d_1	Total number of early syphilis cases by the project area in the reporting period					0
d_2	Total number of cases initiated					0
d_3	Total number of cases interviewed					0
d_4	<i>Interview Rate</i>	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator	
d_5	Total number of contacts (partners) initiated for partner services					0
d_6	<i>Contact Index</i>	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator	
d_7	Total number of contacts examined (tested) within 30 days before or after the index patient's initial specimen collection (Dispo A, B, C, D, E, F, Z)					0
d_8	<i>Exam Rate</i>	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator	
d_9	Total number of contacts previously treated (Dispo E) within 30 days before or after the index patient's initial specimen collection					0

d_10	Total number of contacts preventively treated (Dispo A) within 30 days before or after the index patient's initial specimen collection					0
d_11	Total number of contacts preventively treated (Dispo Z) within 30 days before or after the index patient's initial specimen collection					0
d_12	Total number of contacts brought to Tx for new syphilis infection (Dispo C) within 30 days after the index patient's initial specimen collection					0
d_13	<i>Treatment Index</i>	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator	
d_14	Total number of cases interviewed w/at least 1 contact (partner) treated for syphilis (Dispo A, C, E, Z) within 30 days before or after the index patient's initial specimen collection					0
d_15	<i>Disease Intervention Rate</i>	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator
d_16	<u>Total number of partners brought to treatment (f</u>	0	0	0	0	0
d_17	<i>Total number of new cases of syphilis found through partner services</i>	0	0	0	0	0
d_18	Indicate the quality of the data above by selecting an answer from the dropdown menu. (select your answer twice)					
d_19	Any data limitations, including reasons unable to report (text response)					

STD-Related HIV Prevention in Disease Investigation

Line No.	Metric	Pregnant Females under Age 45 with Early Syphilis	Other Females under Age 45 with Early Syphilis	Men with Only Female Partners (MSW) with Early Syphilis	Men with Male Partners (MSM and MSMW) with Early Syphilis	Men with Male Partners (MSM and MSMW) with GC
e_1	<u>Total number of cases in the project area in the reporting</u>	0	0	0	0	
e_2	<u>Total number of cases initiated (Pre-populated from d 2 o</u>	0	0	0	0	
e_3	<u>Total number of cases interviewed (Pre-populated from d</u>	0	0	0	0	
e_4	Of interviewed, number known to be living with HIV at the time of syphilis (or GC) diagnosis					
e_5	Of interviewed, number newly-diagnosed with HIV within 30 days after syphilis (or GC) diagnosis					
e_6	<i>Among interviewed, overall HIV coinfection rate</i>	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator
e_7	Among interviewed syphilis or GC cases (and not known to be HIV+), % newly-diagnosed with HIV within 30 days after syphilis (or GC) diagnosis	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator
e_8	Indicate the quality of the data above by selecting an answer from the dropdown menu. (select your answer twice)					
e_9	Any data limitations, including reasons unable to report (text response)					

e_10	Of syphilis (or GC) cases newly diagnosed with HIV (e_5), number linked to HIV care within 30 days after new HIV diagnosis					
e_11	Among interviewed and newly diagnosed with HIV, % linked to HIV care within 30 days after new HIV diagnosis	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator
e_12	Indicate the quality of the data above by selecting an answer from the dropdown menu. (select your answer twice)					
e_13	Any data limitations, including reasons unable to report (text response)					
e_14	Of interviewed (and not known to be HIV+), number referred for PrEP after syphilis (or GC) diagnosis					
e_15	Among interviewed (and not known to be HIV+), % referred for PrEP after syphilis (or GC) diagnosis	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator	Enter Denominator
e_16	Indicate the quality of the data above by selecting an answer from the dropdown menu. (select your answer twice)					
e_17	Any data limitations, including reasons unable to report (text response)					

Treatment		
Line No.	Recommended Treatment for Gonorrhea	Data Fields
f_1	For this measure, is the project area reporting on all cases or a sample of cases, based on enhanced GC surveillance? If <u>neither</u> , explain below in Data Notes (f_12) (select from dropdown)	
f_2	Total number of GC cases reported in the reporting period (Overall or among a sample)	
f_7	Total number of GC cases with recommended medication documented (among all or among a sample)	
f_8	Total number of GC cases with recommended medication documented as having been prescribed/received within 14 days of date of specimen collection (among all or among a sample)	
f_9	Among all GC cases, % with recommended medication documented, per CDC guidance (among all or among a sample)	Enter Denominator

f_10	Among all GC cases, % with recommended medication documented within 14 days of the date of specimen collection, per CDC guidance (among all or among a sample)	Enter Denominator
f_11	Indicate the quality of the data above by selecting an answer from the dropdown menu.	
f_12	Any data limitations, including reasons unable to report (text response)	
Line No.	Recommended Treatment for Syphilis	Data Fields
f_13	Total number of early syphilis (ES) cases in the project area in the reporting period	
f_18	Total number of early syphilis cases documented as having been prescribed/received BPG within 14 days of date of specimen collection	
f_18a	(New) Total number of early syphilis cases documented as having been prescribed/received treatment with Doxycycline within 14 days of specimen collection	

f_19	Among early syphilis cases, % treated with BPG within 14 days of specimen collection	Enter Denominator
f_19a	(New) Among early syphilis cases, % treated with Doxycycline within 14 days of specimen collection	Enter Denominator
f_20	Indicate the quality of the data above by selecting an answer from the dropdown menu.	
f_21	Any data limitations, including reasons unable to report (text response)	

Purpose:

- The purpose of this dynamic dashboard is to provide you a sens

Helpful Tips:

- Keep checking this tab as you complete this Excel template to g
- If you want to refer back to the exact part of the template from

Instructions for Use:

- Simply right-click on any visual and click "Copy" (or click on the v
- Open another file, such as a Microsoft Word document or Micro
- Right-click anywhere in that file and click "Paste" (or use the ctrl
- Once pasted, click the dropdown next to the clipboard icon labe

[**Tab A Surveillance**](#)

[Pregnancy Ascertainment](#)

Total Number of Female Syphilis Cases by

Pregnancy Status

Total number of female syphilis cases (all stages) reported in the project area in the reporting period

If yes (a_15): Total number of female syphilis cases (all stages) with pregnancy status documented as "Yes, pregnant" or "No, not pregnant" within 14 days of specimen collection

Key Takeaway: Quickly ascertaining pregnancy status allows your program to prioritize these cases for follow-up and provide more timely case management. Among all female syphilis cases (all stages), the percent with a pregnancy status documented within 14 days of specimen collection is:

Enter Denominator







se of your jurisdiction's performance live while updating this template

et a more complete picture of your performance for this reporting period, which the data for a particular visual originated, click the link above

visual and use the ctrl+c keyboard shortcut).

soft PowerPoint presentation.

+v keyboard shortcut).

led "Ctrl" (or use the ctrl+alt+v keyboard shortcut) to choose the format

Tab B Congenital Syphilis

Potential Cases Averted

Total Number of Congenital Syphilis

Cases and Stillbirths of all Potential Congenital Syphilis Cases

Total number of females with syphilis (all stages) in the project area in the reporting period. (To reference this value, click this link.)

Total number of pregnant females with syphilis (all stages). (To reference this value, click this link.)

Total number of reported congenital syphilis cases and stillbirths

Key Takeaway: The best way to prevent potential cases of congenital syphilis is to prevent syphilis cases in women in general. Continue to assess syphilis cases among women and CS cases for gaps in syphilis testing and treatment and seek to improve. Among all potential congenital syphilis cases, the percent averted is:

Enter Denominator





At-a-Glance

te and to provide you an instant visual ready to use in your own report

period.

the visual.

mat and type of object (e.g. Microsoft Office Graphic Object vs .JPEG

Tab C Outbreak

Active or Initiated STD Outbreak Response Plan(s)

Total Number and Percent of Times that

the Outbreak Plan was Active or Initiated by STD

- Total number of times that the outbreak plan was active or initiated for syphilis by the project area in the reporting period
- Total number of times that the outbreak plan was active or initiated for GC in the reporting period
- Total number of times that the outbreak plan was active or initiated for another STD in the reporting period

Key Takeaway: This visual depicts the total number and percent of times an outbreak plan was active or initiated for various STDs in this reporting period.

Staff Assignments to Assist Other Outbreaks

Total Number and Percent of STD Staff Who were Deployed for All Outbreaks (STD and Non-STD)

- Total number of STD program staff deployed on temporary, formal assignments to assist with HIV, Hepatitis, or TB outbreaks during the reporting period
- Total number of STD program staff deployed on temporary, formal assignments to assist with non-STD (e.g. foodborne, etc.) outbreaks during the reporting period

Key Takeaway: Among all STD program staff deployed to assist with outbreaks, the percent of staff deployed for non-STD outbreaks in this reporting period is:

Enter Denominator



Dashboard

orting and documentation.


picture, etc.) of the visual as you would like it pasted into your document.

Tab D Syphilis DII

Early Syphilis Cases: Disease Investigation and Intervention

Total Number of Early Syphilis Cases

Interviewed, by Key Population



Key Takeaway: The higher the number of cases interviewed, the greater chance for contact elicitation, exam, and potential disease intervention.

[Disease Intervention Rate](#)

Disease Intervention Rate by Key Population

Men with Male Partners (MSM and MSMW)							
Men with only Female Partners (MSW)							
Other Females under Age 45							
Pregnant Females under Age 45							

Key Takeaway: The higher the Disease Intervention Rate (DIR), the more your program intervened in the spread of syphilis. The Total DIR across all key populations is:

Enter Denominator

[DoxyPEP for Bacterial STI Prevention](#)


**Total Number of Priority Medical
Providers, including those Administering
DoxyPEP**

Total number of Priority Medical Practices (STD clinic/Non-STD Clinic) identified in jurisdiction							
Total number of Priority Medical Practices (STD clinic/Non-STD Clinic) identified in jurisdiction that provide DoxyPEP to patients							

--	--	--	--	--	--	--	--	--

Key Takeaway: The higher the percentage of Priority Medical Providers (STD clinic/Non-STD Clinic) prescribing DoxyPEP to their patients, the greater the chance of preventing bacterial STIs such as syphilis. The percentage of Priority Medical Providers (STD clinic/Non-STD Clinic) prescribing DoxyPEP in this reporting period is:

Enter Denominator



ment or presentation.

Tab E HIV Prevention DII

Newly Diagnosed HIV Cases Among Syphilis or GC Cases

Among Interviewed Early Syphilis Cases

(and not known to be HIV+), Percent Newly-Diagnosed with HIV within 30 days after Early Syphilis Diagnosis, by Key Population

Pregnant Females under Age 45 with Early Syphilis									
Other Females under Age 45 with Early Syphilis									
Men with Only Female Partners (MSW) with Early Syphilis									
Men with Male Partners (MSM and MSMW) with Early Syphilis									

Key Takeaway: The higher the newly HIV diagnosed percentage, the more significant HIV testing of syphilis cases is to detecting HIV infections and getting them linked to care to interrupt transmission.

HIV Linkage to Care

Among Interviewed and Newly Diagnosed with HIV, Percent Linked to HIV Care within 30 Days after New HIV Diagnosis by Key Population

Pregnant Females under Age 45 with Early Syphilis								
Other Females under Age 45 with Early Syphilis								
Men with Only Female Partners (MSW) with Early Syphilis								
Men with Male Partners (MSM and MSMW) with Early Syphilis								

Key Takeaway: The higher the HIV linkage to care percentage, the more likely it is your program will prevent spread and progression of HIV to AIDS.

PrEP Referral Percentage Post Syphilis Diagnosis

**Among Early Syphilis Cases Interviewed
(and not known to be HIV+), % Referred
for PrEP, by Key Population**

Pregnant Females under Age 45 with Early Syphilis							
Other Females under Age 45 with Early Syphilis							
Men with Only Female Partners (MSW) with Early Syphilis							

Men with Male Partners (MSM and MSMW) with Early Syphilis							
---	--	--	--	--	--	--	--

Key Takeaway: The higher the PrEP referral percentage, the greater the chance of preventing the acquisition of HIV infection.



Tab F Treatment

Recommended Treatment for Syphilis

Total Number and Percent of Early

Syphilis Cases Treated with BPG or Doxycycline

- Total number of early syphilis cases documented as having been prescribed/received BPG within 14 days of date of specimen collection
- (New) Total number of early syphilis cases documented as having been prescribed/received treatment with Doxycycline within 14 days of specimen collection

Key Takeaway: BPG is the recommended CDC treatment. A higher percentage of early syphilis (ES) cases treated with BPG is optimal. The percentage of ES cases treated with BPG is:

Enter Denominator





Optional Feedback		
Line No.	Question	Response
q1	Did you find the notes and instructions provided for each response useful? Please select your answer from the dropdown menu.	
q2	Did you find the UI improvements (e.g. color-coded data entry and reference links) useful? Please select your answer from the dropdown menu.	
q3	<u>Did you find the Dashboard tab useful? Please select your answer from the dropdown menu.</u>	
q4	<u>Did you attempt to cut and paste the graphics from the Dashboard? Please select your answer from the dropdown menu.</u>	
q5	Above, why or why not did you attempt to cut and paste the graphics? If you answered yes to #3, briefly describe how that process went for you. (text response)	

q6

Overall, please share any additional thoughts or feedback you have about the template. (text response)

General Description of Safety Net Assistance (SNA)		
Line No	Description	Data Fields
sna_1	Approximately what % of the STD PCHD budget did the project area devote to safety net assistance in the reporting period?	[Select from Dropdown]
sna_2	Did the project area specifically focus the safety net assistance towards any of the following demographic groups? (select all that apply)	Adolescents/young adults
sna_3		MSM
sna_4		Pregnant women
sna_5		No, none of these groups were specifically focused on (though they may have benefited). (Select Yes only if sna_2, sna_3, and sna_4 were all answered as No)
sna_6	What were the <u>main formal criteria</u> used for selecting which providers or organizations were eligible to access the safety net assistance (SNA) or were funded for SNA? (select all that apply)	They met a certain threshold for positivity for testing
sna_7		They met a certain threshold for STD disease morbidity or a certain STD case count or rate
sna_8		They served under/uninsured populations
sna_9		They served other priority populations or geographic areas in need of subsidized services
sna_10		They had a track record of effective partnership with us
sna_11		Other: (please write answer below in sna_46 text box)
sna_12		I'm not sure/don't know of the main formal criteria that was used (If answered as Yes, please provide further context in sna_46)
sna_13		Which STD clinical prevention services did the safety net assistance support? Select all that apply.
sna_14	CT/GC extragenital testing/screening	
sna_15	CT/GC treatment, including EPT	
sna_16	Syphilis testing/screening	
sna_17	Syphilis treatment	
sna_18	Other STD clinical preventive service: (please write answer below in sna_46 text box)	
sna_19	Which types of providers were funded directly by the project area for safety net assistance (SNA) or were given the opportunity to take advantage of the SNA during the reporting period? Select all that	
sna_20		Local health department clinics (general)
sna_21		Family planning/ reproductive health clinics
sna_22		Maternal and child health programs
sna_23		HIV prevention or care clinics
sna_24		Behavioral or mental health agencies, including drug treatment
sna_25		Federally-qualified health centers (FQHC) or other community health centers
sna_28		Correctional facilities (prison, jail, juvenile detention)
sna_29		School-based, college, or university health centers

sna_30	Reporting period: Select all that apply.	Tribal or Indian Health Service health care centers	[Select from Dropdown]
sna_31		Other non-profit, private health care providers or organizations (e.g., CBOs)	[Select from Dropdown]
sna_32		Other private health care providers or organizations	[Select from Dropdown]
sna_33		Others not listed: (please write answer below in sna_46 text box)	[Select from Dropdown]
sna_34		We don't know/ aren't sure	[Select from Dropdown]
	What are the primary mechanisms through which the project area provided the safety net assistance (SNA)? Select all that apply.	Often found in Contract budget line:	
sna_35		(A) Direct contracts or subgrants with health care organizations or providers for safety net assistance only	[Select from Dropdown]
sna_36		(B) Direct contracts or subgrants with health care organizations or providers for various services that include safety net assistance	[Select from Dropdown]
sna_37		(C) Direct contracts or subgrants with lab(s) (public or private) to conduct testing for certain providers	[Select from Dropdown]
		Often found in Supplies, Other, or Personnel:	
sna_38		(D) Purchase of test kits or treatment/EPT, which are then distributed or allocated to certain providers by us	[Select from Dropdown]
sna_39		(E) Support all/part of the salary of lab(s) staff to conduct testing for certain providers or types of tests	[Select from Dropdown]
sna_40		(F) Other: (please write answer below in sna_46 text box)	[Select from Dropdown]
sna_41	Did the project area combine the STD PCHD safety net assistance with funding from other sources, to fund those contracts/ subgrants (A-C), to make those purchases (D), or support those staff (E)? Select all that apply.	Yes, we added state (or local) project area funds (e.g. STD, general)	[Select from Dropdown]
sna_42		Yes, we added federal funds (e.g., HIV, Title X, HRSA)	[Select from Dropdown]
sna_43		Yes, we added other funding sources	[Select from Dropdown]
sna_44		No, STD PCHD was the only funding we put into those contracts/subgrants/purchases	[Select from Dropdown]
sna_45		Don't know/ too unsure to answer	[Select from Dropdown]
	(Optional) Please provide any other information you would like to add about your approach to providing SNA in the reporting period, or answers to question on this worksheet for which you selected "Other":		
sna_46			
		Often found in Contract budget line:	
sna_47		(A) Direct contracts or subgrants with health care organizations or providers for safety net assistance only	[Select from Dropdown]
sna_48		(B) Direct contracts or subgrants with health care organizations or providers for various services that include safety net assistance	[Select from Dropdown]

sna_49	For which parts of your safety net assistance do you have data on tests conducted, test results, or treatment purchased?	(C) Direct contracts or subgrants with lab(s) (public or private) to conduct testing for certain providers	[Select from Dropdown]
		Often found in Supplies, Other, or Personnel:	
sna_50		(D) Purchase of test kits or treatment/EPT, which are then distributed or allocated to certain providers by us	[Select from Dropdown]
sna_51		(E) Support all/part of the salary of lab(s) staff to conduct testing for certain providers or types of tests	[Select from Dropdown]
sna_52		(F) Other: (please write answer above in sna_46 text box)	[Select from Dropdown]
sna_53		We do not have any data at this time (please provide reason why not, above in sna_46 text box)	[Select from Dropdown]
If A-F is selected, please complete an "Admin_SNA_test_TX_data" worksheet for each mechanism selected. Up to 3 total.			

Complete 1 table per mechanism selected in SNA_Overall				
Line No.	Description	Data Fields	Data Fields	Data Fields
sna_54	Which mechanism does the following refer to?	[Select from Drop down]		
sna_55	Which of the following groups of clients does the following testing data refer to?	[Select from Dropdown]		
	How many tests were conducted?	Syphilis tests performed	GC tests performed	CT tests performed
sna_56	Total tests conducted			
sna_57	All Males			
sna_58	Males, 15-24 years			
sna_59	Males, 25-44			
sna_60	Males, 45+			
sna_61	All Females			
sna_62	Females, 15-24 years			
sna_63	Females, 25-44			
sna_64	Females, 45+			
	Of those tests, how many were positive or reactive?	Positive Syphilis tests	Positive GC tests	Positive CT tests
sna_65	Total positive or reactive tests			
sna_66	All Males			
sna_67	Males, 15-24 years			
sna_68	Males, 25-44			
sna_69	Males, 45+			
sna_70	All Females			
sna_71	Females, 15-24			
sna_72	Females, 25-44			
sna_73	Females, 45+			
	Positivity	Among Syphilis tests performed	Among GC tests performed	Among CT tests performed
sna_74	Total tests	Enter Denominator	Enter Denominator	Enter Denominator
sna_75	All Males	Enter Denominator	Enter Denominator	Enter Denominator
sna_76	Males, 15-24 years	Enter Denominator	Enter Denominator	Enter Denominator
sna_77	Males, 25-44	Enter Denominator	Enter Denominator	Enter Denominator
sna_78	Males, 45+	Enter Denominator	Enter Denominator	Enter Denominator
sna_79	All Females	Enter Denominator	Enter Denominator	Enter Denominator
sna_80	Females, 15-24	Enter Denominator	Enter Denominator	Enter Denominator
sna_81	Females, 25-44	Enter Denominator	Enter Denominator	Enter Denominator
sna_82	Females, 45+	Enter Denominator	Enter Denominator	Enter Denominator
	Treatment medication (if any purchased with STD PCHD safety net assistance)	Syphilis medication	GC medication	CT medication
sna_83	Total medication units purchased in reporting period. Please write in units tracked by your program (e.g. "X# BIC injections" or "Y# pills" or "Z# patient TX packs.")			
	If you are unable to provide the above information on the tests performed, test results, or treatment purchases attributable to STD PCHD, please explain why not:			
sna_84				
	(Optional) Please provide any other information you would like to add about the treatment or patient testing data that you provided on the safety net assistance in the reporting period:			
sna_85				

Complete 1 table per mechanism selected in Admin_SNA_overall

Line No.	Descripton	Data Fields	Data Fields	Data Fields
sna_54	Which mechanism does the following refer to?	[Select from Drop down]		
sna_55	Which of the following groups of clients does the following testing data refer to?	[Select from Dropdown]		
	How many tests were conducted?	Syphilis tests performed	GC tests performed	CT tests performed
sna_56	Total tests conducted			
sna_57	All Males			
sna_58	Males, 15-24 years			
sna_59	Males, 25-44			
sna_60	Males, 45+			
sna_61	All Females			
sna_62	Females, 15-24 years			
sna_63	Females, 25-44			
sna_64	Females, 45+			
	Of those tests, how many were positive or reactive?	Positive Syphilis tests	Positive GC tests	Positive CT tests
sna_65	Total positive or reactive tests			
sna_66	All Males			
sna_67	Males, 15-24 years			
sna_68	Males, 25-44			
sna_69	Males, 45+			
sna_70	All Females			
sna_71	Females, 15-24			
sna_72	Females, 25-44			
sna_73	Females, 45+			
	Positivity	Among Syphilis tests performed	Among GC tests performed	Among CT tests performed
sna_74	Total tests	Enter Denominator	Enter Denominator	Enter Denominator
sna_75	All Males	Enter Denominator	Enter Denominator	Enter Denominator
sna_76	Males, 15-24 years	Enter Denominator	Enter Denominator	Enter Denominator
sna_77	Males, 25-44	Enter Denominator	Enter Denominator	Enter Denominator
sna_78	Males, 45+	Enter Denominator	Enter Denominator	Enter Denominator
sna_79	All Females	Enter Denominator	Enter Denominator	Enter Denominator
sna_80	Females, 15-24	Enter Denominator	Enter Denominator	Enter Denominator
sna_81	Females, 25-44	Enter Denominator	Enter Denominator	Enter Denominator
sna_82	Females, 45+	Enter Denominator	Enter Denominator	Enter Denominator
	Treatment medication (if any purchased with STD PCHD safety net assistance)	Syphilis medication	GC medication	CT medication
sna_83	Total medication units purchased in reporting period. Please write in units tracked by your program, e.g. "X# BIC injections" or "Y# pills" or "Z# patient TX packs."			
	If you are unable to provide the above information on the tests performed, test results, or treatment purchases attributable to STD PCHD, please explain why not:			
sna_84				
	(Optional) Please provide any other information you would like to add about the treatment or patient testing data that you provided on the safety net assistance in the reporting period:			
sna_85				

Complete 1 table per mechanism selected in Admin_SNA_overall

Line No.	Descripton	Data Fields	Data Fields	Data Fields
sna_54	Which mechanism does the following refer to?	[Select from Drop down]		
sna_55	Which of the following groups of clients does the following testing data refer to?	[Select from Dropdown]		
	How many tests were conducted?	Syphilis tests performed	GC tests performed	CT tests performed
sna_56	Total tests conducted			
sna_57	All Males			
sna_58	Males, 15-24 years			
sna_59	Males, 25-44			
sna_60	Males, 45+			
sna_61	All Females			
sna_62	Females, 15-24 years			
sna_63	Females, 25-44			
sna_64	Females, 45+			
	Of those tests, how many were positive or reactive?	Positive Syphilis tests	Positive GC tests	Positive CT tests
sna_65	Total positive or reactive tests			
sna_66	All Males			
sna_67	Males, 15-24 years			
sna_68	Males, 25-44			
sna_69	Males, 45+			
sna_70	All Females			
sna_71	Females, 15-24			
sna_72	Females, 25-44			
sna_73	Females, 45+			
	Positivity	Among Syphilis tests performed	Among GC tests performed	Among CT tests performed
sna_74	Total tests	Enter Denominator	Enter Denominator	Enter Denominator
sna_75	All Males	Enter Denominator	Enter Denominator	Enter Denominator
sna_76	Males, 15-24 years	Enter Denominator	Enter Denominator	Enter Denominator
sna_77	Males, 25-44	Enter Denominator	Enter Denominator	Enter Denominator
sna_78	Males, 45+	Enter Denominator	Enter Denominator	Enter Denominator
sna_79	All Females	Enter Denominator	Enter Denominator	Enter Denominator
sna_80	Females, 15-24	Enter Denominator	Enter Denominator	Enter Denominator
sna_81	Females, 25-44	Enter Denominator	Enter Denominator	Enter Denominator
sna_82	Females, 45+	Enter Denominator	Enter Denominator	Enter Denominator
	Treatment medication (if any purchased with STD PCHD safety net assistance)	Syphilis medication	GC medication	CT medication
sna_83	Total medication units purchased in reporting period. Please write in units tracked by your program, e.g. "X# BIC injections" or "Y# pills" or "Z# patient TX packs."			
	If you are unable to provide the above information on the tests performed, test results, or treatment purchases attributable to STD PCHD, please explain why not:			
sna_84				
	(Optional) Please provide any other information you would like to add about the treatment or patient testing data that you provided on the safety net assistance in the reporting period:			
sna_85				